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The molecular characterization of 218 GBS isolates recovered from neonatal invasive
infections in Portugal in 2005–2015 revealed the existence of a small number of
genetically distinct lineages that were present over a significant time-span. Serotypes
III and Ia were dominant in the population, together accounting for >80% of the
isolates. Clonal complex 17 included 50% of all isolates, highlighting the importance
of the hypervirulent genetic lineage represented by serotype III ST17/rib/PI-1+PI-2b.
Serotype Ia was represented mainly by ST23, previously reported as dominant among
invasive disease in non-pregnant adults in Portugal, but also by ST24, showing an
increased frequency among late-onset disease. Overall erythromycin resistance was
16%, increasing during the study period (p < 0.001). Macrolide resistance was
overrepresented among CC1 and CC19 isolates (p< 0.001 and p= 0.008, respectively).
While representatives of the hypervirulent CC17 lineage were mostly susceptible to
macrolides, we identified for the first time in Europe a recently emerging sublineage
characterized by the loss of PI-1 (CC17/PI-2b), simultaneously resistant to macrolides,
lincosamides, and tetracycline, also exhibiting high-level resistance to streptomycin and
kanamycin. The stability and dominance of CC17 among neonatal invasive infections
in the past decades indicates that it is extremely well adapted to its niche; however
emerging resistance in this genetic background may have significant implications for the
prevention and management of GBS disease.
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INTRODUCTION
Streptococcus agalactiae, or group B streptococci (GBS), is a leading cause of severe neonatal
infections (Edmond et al., 2012), while also being a frequent colonizer of the genitourinary
and gastrointestinal tracks of a significant proportion of the human population. The onset
of GBS infections takes place early in infancy, usually within the first week of life, being
designated early-onset disease (EOD). Late-onset disease (LOD) develops after the first week
until 3 months of age. Maternal colonization with GBS is the leading risk factor for
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the development of neonatal disease, but other sources of
transmission exist (Manning et al., 2004).
Even though national health authorities formally
implemented universal GBS screening of pregnant women
only in 2013 (Norma 37/2011, 2013), the neonatology section
of the Portuguese Society of Paediatrics issued guidelines for
screening and prevention of GBS perinatal disease in 2004.
These recommended universal screening of pregnant women at
35–37 weeks gestation and the administration of intrapartum
antimicrobial prophylaxis (IAP) to GBS carriers (Pinheiro
et al., 2013). Following the publication of these guidelines, a
study based on voluntary reporting of GBS neonatal disease
in Portugal described reductions in the incidence of EOD
of nearly 40%, as well as of the case-fatality rate associated
(Neto, 2008), in agreement with what had been observed in
other countries where similar measures were implemented
(Verani et al., 2010).
Penicillin is the first line agent for prevention and treatment of
GBS disease, while clindamycin and vancomycin are considered
suitable alternatives for penicillin-allergic patients (Verani et al.,
2010). GBS is mostly considered uniformly susceptible to β-
lactams. In contrast, increasing resistance to erythromycin and
clindamycin in both neonatal and adult invasive infections
have been reported worldwide in recent years (Castor et al.,
2008; Lamagni et al., 2013), raising concern as to the long-
term efficacy of current prophylatic and therapeutic strategies.
Development of a universal vaccine is the most promising
approach to fight GBS disease, given the potential adverse effects
of IAP and the need for effective prevention of both neonatal
and adult infections. In recent years, capsular polysaccharide
conjugated vaccines have reached phase II clinical trials while a
pilus-based vaccine is also being investigated (Nuccitelli et al.,
2015).
Serotyping is the classical phenotypic typing method for
the characterization of GBS, allowing their classification into
capsular polysaccharide-based serotypes Ia to IX. More recently,
genotypic tools such as multilocus sequence typing (MLST) have
contributed to the recognition of particular genetic lineages
within serotypes that were shown to differ in virulence potential
and tropism (Jones et al., 2003). The combination of several
typing methods, including surface protein gene (Creti et al.,
2004) and pilus-islands (Martins et al., 2013) profiling were
shown to afford increased discriminatory power. Currently, a
genetic lineage of serotype III defined by sequence type 17
(ST17), surface protein rib and the combination of pilus islands
1 and 2b is disseminated worldwide and is associated with an
increased ability to cause neonatal invasive disease, particularly
meningitis (Manning et al., 2009; Meehan et al., 2014). On
the other hand, invasive disease among adults has been mostly
attributed to the serotype Ia/ST23/eps and serotype V/ST1/alp3
clones (Lamagni et al., 2013; Meehan et al., 2014; Teatero et al.,
2014).
The aim of our study was to perform the characterization of a
collection of GBS isolates recovered from neonates with invasive
disease in Portugal in 2005–2015, to document the prevalence
of serotypes, genetic lineages and antimicrobial resistance
patterns.
MATERIALS AND METHODS
Bacterial Isolates
This work was part of a laboratory-based surveillance program
in which microbiology laboratories of 22 Portuguese hospitals
or hospital centers were asked to submit to a central laboratory
all GBS isolates recovered from cases of neonatal GBS invasive
disease.
Cases were classified into three presentations: EOD (early-
onset disease), defined as disease onset from birth to 6 days after
birth; LOD (late-onset disease), for patients ranging from 7 to 90
days of age; and ULOD (ultra-late-onset disease), in which the
patients were older than 91 days of life but <1 year. Whenever,
GBS isolates were available from more than one sample from
the same patient, only the first isolate was included in the
study. Identification was confirmed to the species level by Gram
stain, colony morphology, and a commercial latex agglutination
technique (Slidex Strepto B; bioMérieux, Marcy L’Étoile, France).
Serotyping
Capsular serotyping was performed by a slide agglutination
assay with IMMULEXTM STREP-B Kit (Statens Serum Institute,
Copenhagen, Denmark) according to the manufacturer’s
instructions.
Antimicrobial Susceptibility Testing
Susceptibility testing was performed by disc diffusion according
to the Clinical and Laboratory Standards Institute (CLSI)
methods and interpretation criteria for Streptococcus spp. β-
Hemolytic Group (Clinical Laboratory Standards Institute,
2014). The panel of antibiotics included penicillin G,
erythromycin, clindamycin, vancomycin, chloramphenicol,
levofloxacin, and tetracycline. We have also performed a
screening test by disk diffusion for detection of High-Level
Aminoglycoside Resistance (HLAR), with 120 µg gentamicin
and 300 µg streptomycin disks, according to the CLSI methods
and interpretative criteria for Enterococcus species (Clinical
Laboratory Standards Institute, 2014). Susceptibility testing of
kanamycin and lincomycin was performed as recommended
by the Société Française de Microbiologie (http://www.sfm-
microbiologie.org).
Resistance tomacrolides only (M phenotype); and constitutive
or inducible cross-resistance to macrolides, lincosamides and
streptogramin B (cMLSB and iMLSB phenotypes, respectively),
were determined by a double-disk test with erythromycin
and clindamycin. The presence of macrolide resistance genes
was detected by multiplex PCR targetting the erm(B), erm(A)
[erm(TR) subclass], and mef [mef (A) or mef (E)] genes (Martins
et al., 2012), and by an additional PCR for the erm(T) gene
(Compain et al., 2014). The presence of lincosamide resistance
genes lsa(C) (Malbruny et al., 2011) and lnu(B) (Bozdogan et al.,
1999) was also tested by PCR.
All tetracycline-resistant isolates were screened for
the presence of the tet(K), tet(L), tet(M), and tet(O)
genes, as previously described (Martins et al., 2012). The
genetic determinants of High-Level Resistance (HLR) to
aminoglycosides aac(6′)-aph(2′′), aph(2′′)-Ib, aph(2′′)-Ic,
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aph(2′′)-Id, aph(3′)-III, ant(4′)-Ia, and ant(6)-Ia were tested by
PCR as described for enterococci (Clark et al., 1999; Vakulenko
et al., 2003).
MLST
MLST was performed as described previously (Jones et al.,
2003) and sequence type (ST) assignment was done according to
the S. agalactiaeMLST database (http://pubmlst.org/sagalactiae).
Analysis of DNA sequences was performed by using the
Bionumerics software (Applied Maths, Sint-Martens-Latem,
Belgium). Alleles and sequence types not previously described
were deposited in the S. agalactiae MLST database. The
goeBURST algorithm implemented in PHYLOViZ software
(Nascimento et al., 2017) was used to establish relationships
between STs. Clonal complexes (CCs) were defined at the single-
locus-variant (SLV) level.
Surface Protein Gene Profile and Pili
The GBS alpha (bca) and alpha-like (eps, rib, alp2/3, and alp4)
protein genes were detected by amultiplex PCR assay (Creti et al.,
2004), and the alp2 and alp3 genes differentiated as previously
described (Martins et al., 2010).
All isolates were tested for the presence of PI-1, PI-2a, and
PI-2b loci by PCR (Martins et al., 2013).
Typing Analysis and Statistics
Information about the number of live births in Portugal was
obtained from Statistics Portugal (http://www.ine.pt).
Simpson’s index of diversity (SID) and 95% confidence
intervals (CI95%) was used to estimate the diversity found among
the isolates studied (www.comparingpartitions.info; Carrico
et al., 2006).
Differences were evaluated by the Fisher exact test with
the false discovery rate (FDR) correction for multiple testing
(Benjamini and Hochberg, 1995). The Cochran-Armitage test
was used for trends. A p < 0.05 was considered significant for
all tests.
Ethics Statement
Case reporting and isolate collection were considered
surveillance activities and were exempt from evaluation by
the Review Board of the Faculdade de Medicina da Universidade
de Lisboa. The data and isolates were de-identified so that these
were irretrievably unlinked to an identifiable person.
RESULTS
Isolates
Between 2005 and 2015, 218 cases of neonatal invasive group
B streptococcal infections were identified, including 188 isolates
recovered from blood, 26 from cerebrospinal fluid, 3 from
synovial fluid, and one from ascitic fluid. There was a higher
number of EOD cases (n = 113), followed by LOD (n = 101)
and 4 ULOD cases (Table 1). The number of births in Portugal
declined during the study period and there were yearly variations
in disease cases (Figure 1, Supplementary Table 1). For the
purpose of statistical analysis ULOD cases were included in LOD.
TABLE 1 | Serotype distribution according to disease onset.
Serotype Disease onset, no. (%)a Total no (%)
EOD LOD ULOD
Ia 26 (11.9) 22 (10.1) 0 48 (22.0)
Ib 8 (3.7) 3 (1.4) 1 (0.5) 12 (5.5)
II 9 (4.1) 0 0 9 (4.1)
III 59 (27.1) 67 (30.7) 2 (0.9) 128 (58.7)
IV 0 3 (1.4) 0 3 (1.4)
V 4 (1.8) 5 (2.3) 0 9 (4.1)
VI 1 (0.5) 0 0 1 (0.5)
VIII 1 (0.5) 0 0 1 (0.5)
IX 1 (0.5) 0 0 1 (0.5)
NTb 4 (1.8) 1 (0.5) 1 (0.5) 6 (2.8)
Total 113 (51.8) 101 (46.3) 4 (1.8) 218 (100.0)
aEOD, early-onset disease; LOD, late-onset disease; ULOD, ultra-late-onset disease.
bNT, non-typeable.
Serotype Distribution
Serotyping results are summarized in Table 1. Overall serotypes
were similarly distributed among EOD and LOD (p = 0.063),
except serotype II that was exclusively represented in EOD, and
the three serotype IV isolates that were recovered from LOD cases
(Table 1). No statistically significant associations were found
between serotype and isolate source. Serotypes III (n= 128; 59%)
and Ia (n = 48; 22%) were the most frequent in the population,
together accounting for 81% of the isolates. In spite of almost
all known GBS serotypes having been found, including serotypes
VIII and IX here described for the first time in Portugal, diversity
was low (SID= 0.602, CI95% 0.540–0.665).
Genetic Lineages
According to MLST, the 218 isolates presented a high
genetic diversity, being distributed across 35 sequence types
(SID = 0.789, CI95% 0.738–0.839), of which six (ST742–745,
ST757, and ST878) were newly identified in this study. The
STs clustered into 7 clonal complexes. The distribution of STs,
serotypes, surface protein and pilus genes, as well as antimicrobial
resistance genotypes across CCs is shown in Table 2.
Half of the collection was represented by CC17 (n = 109;
50%), including the serotype III hypervirulent lineage defined by
ST17 and its SLVs, surface protein gene rib and the combination
of PI-1 and PI-2b. CC17 was overrepresented in LOD cases
(p = 0.007), in agreement with our previous findings and those
reported elsewhere (Manning et al., 2009; Martins et al., 2011;
Meehan et al., 2014).
Serotype Ia was found in CC23, includingmostly ST23/eps/PI-
2a, but also a sublineage constituted by a double-locus variant
of ST23 represented by ST24/bca/PI-2a, which has been mostly
detected in the Mediterranean region (Martins et al., 2011). ST23
and ST24 and corresponding SLVs were largely distinguished
according to disease onset: while ST23 and SLVs (ST88, ST144,
and ST745) were dominant among EOD cases (n = 23/26,
88.5%), 14 out of the 17 isolates (82.3%) represented by ST24
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FIGURE 1 | Invasive neonatal disease cases and live births in Portugal by year.
and SLVs (ST452 and ST498) were recovered from LOD cases
(p < 0.001).
A small number of isolates was represented by ST1 and the
combination of surface protein gene alp3 and pilus islands 1 and
2a, a genetic background that is usually associated with serotype
V. However, out of the 13 isolates identified as ST1/alp3/PI-
1+PI-2a, 7 presented serotype Ib and only 6 the expected
serotype V.
Antimicrobial Susceptibility Testing
All isolates were susceptible to penicillin, vancomycin and
levofloxacin. Gentamicin, chloramphenicol and streptomycin
resistance was found in 0.5% (n = 1), 1.4% (n = 3), and 3.2%
(n= 7) of the isolates, respectively.
The overall rate of erythromycin resistance was 16.1% (n= 35)
and of clindamycin 14.2% (n = 31). Macrolide resistance
increased throughout the study period (Cochran-Armitage test
of trend, p < 0.001) (Figure 2), mainly represented by the
cMLSB phenotype (n = 25), followed by iMLSB (n = 6) and
M (n = 4) phenotypes. Even though no isolates resistant
only to clindamycin were detected, one isolate presenting the
cMLSB phenotype carried both the erm(B) and lsa(C) genes
(Table 2), while the lnu(B) gene was not found in any isolate.
Macrolide resistance was significantly associated with CC1 and
CC19 (p < 0.001 and p = 0.008, respectively), contrasting
with CC17 and CC23 in which it was underrepresented (both
cases, p = 0.03). Interestingly, within CC17 there was a
subset of isolates carrying only PI-2b in which macrolide
resistance was overrepresented (p< 0.001). Most of these isolates
also presented HLR to streptomycin, harboring two genetic
determinants encoding aminoglycoside-modifying enzymes,
aph(3′)-III and ant(6)-Ia (Table 2). Additional antimicrobial
susceptibility testing performed on this subset revealed that all
isolates were also resistant to kanamycin and lincomycin.
The single gentamicin resistant isolate was also found
within CC17, (Table 2), carrying the aac(6′)-aph(2′′) gene,
which encodes a bifunctional aminoglycoside-modifying enzyme
known to mediate HLR to virtually all clinically available
aminoglycosides, but not to streptomycin (Vakulenko et al.,
2003).
A high percentage of isolates was resistant to tetracycline
(n = 187; 85.8%). The resistance determinant most frequently
found was tet(M) (n = 182/187; 97.3%), but different
combinations of tet genes were also found in a small fraction
of the isolates. Within the abovementioned subset of CC17
presenting only PI-2b, all isolates carried the tet(O) gene
(Table 2).
DISCUSSION
This study presents the characterization of GBS recovered from
invasive infections among neonates in Portugal in 2005–2015.
Even though our network comprised most of the hospital
microbiology laboratories in Portugal, this study was based
on voluntary reporting and is therefore not population based.
Notwithstanding, our surveillance network is stable and we
consider that any differences observed reflect true variations in
cases, still given potentially incomplete reporting we refrained
from calculating incidences of GBS disease in Portugal.
No information about the implementation and effectiveness
of screening recommendations and IAP are available in Portugal
from official sources. When these measures started being
implemented at hospital level in Portugal, a decreasing incidence
of neonatal GBS disease in 2002–2004 was found, particularly
among EOD cases, suggesting that the recent implementation
of IAP was already having a beneficial impact (Neto, 2008). In
contrast, when comparing the number of neonatal infections
with the number of live births in Portugal in 2005–2015
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TABLE 2 | Distribution of serotypes, surface protein, pili and antimicrobial resistance profiles among MLST-based clonal complexes.
Genetic
lineagea
Serotypeb
(n)
Alp
genec
Pilus island Macrolide resistance
phenotyped (n)
Antimicrobial resistance genotypee (n)
CC1 (n = 21)
ST1 Ib (7) alp3 PI-1+PI-2a cMLSB(6) ermB(6), tetM(7)
V (6) alp3 PI-1+PI-2a cMLSB(3) ermB(2), ermTR(1), tetM(2)
VI (1) bca PI-1+PI-2a
ST2 V (2) eps PI-1+PI-2a tetM(1)
Ib (1) eps PI-2a
NT (1) eps PI-2a tetM(1)
ST196 IV (1) eps PI-1+PI-2a tetM(1)
Ia (1) eps PI-1+PI-2a tetM(1)
ST878 NT (1) alp3 PI-1+PI-2a cMLSB ermB, tetM(1)
CC10 (n = 9)
ST10 Ib (1) eps PI-1+PI-2a tetM(1)
NT (2) eps PI-1+PI-2a
ST8 Ib (1) bca PI-1+PI-2a tetM(1)
ST9 Ib (1) bca PI-1+PI-2a
ST12 II (2) bca PI-1+PI-2a tetM(1), tetO(1)
Ib (1) bca PI-1+PI-2a cMLSB ermB, tetM(1)
V (1) eps PI-1+PI-2a tetM(1)
CC17 (n = 109)
ST17 III (93) rib PI-1+PI-2b cMLSB(2), M(1) ermB(2), mefE(1), tetM(70), tetM+tetL(3), tetM+tetO(2), aac(6
′)-aph(2′′) (1)
III (8) rib PI-2b cMLSB(7) ermB(7), tetM+tetO(4), tetO(3), aph(3
′)-III+ant(6)-Ia(6)
ST757 III (1) rib PI-2b cMLSB(1) ermB, tetM+tetO, aph(3
′)-III+ant(6)-Ia(1)
ST109 III (6) rib PI-1+PI-2b tetM(1)
ST147 III (1) rib PI-1+PI-2b tetM(1)
ST287 III (2) rib PI-1+PI-2b tetM(1)
ST290 III (1) rib PI-1+PI-2b tetM(1)
ST450 III (1) rib PI-1+PI-2b tetM(1)
ST482 III (1) rib PI-1+PI-2b tetM+tetL(1)
ST550 III (1) rib PI-1+PI-2b tetM(1)
ST743 III (1) rib PI-1+PI-2b tetM(1)
ST744 III (1) rib PI-1+PI-2b tetM(1)
CC19 (n = 25)
ST19 III (14) rib PI-1+PI-2a cMLSB(2), iMLSB (5) ermB(1), ermB+lsaC(1), ermTR(5), tetM(10)
ST27 III (1) rib PI-1+PI-2a tetM+tetO(1)
ST28 II (5) rib PI-1+PI-2a tetM(5)
VIII (1) rib PI-1+PI-2a
ST182 III (1) rib PI-1+PI-2a cMLSB ermB, tetO(1)
ST335 III (1) rib PI-1+PI-2a iMLSB ermTR, tetM(1)
ST510 III (1) rib PI-1+PI-2a tetM(1)
ST742 III (1) rib PI-1+PI-2a tetM(1)
CC22 (n = 3)
ST22 II (2)
NT (1)
bca
bca
PI-1+PI-2a
PI-1+PI-2a
cMLSB(1) ermB(1), tetM(1)
tetM(1)
CC23 (n = 50)
ST23 Ia (29) eps PI-2a M(3) mefE(3), tetM(29)
tetM+tetO(1)NT (1) bca PI-1+PI-2a
ST88 Ia (1) alp2 PI-1+PI-2a
ST144 Ia (1) rib PI-2a tetM(1)
ST745 Ia (1) eps PI-2a tetM(1)
(Continued)
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TABLE 2 | Continued
Genetic
lineagea
Serotypeb
(n)
Alp
genec
Pilus island Macrolide resistance
phenotyped (n)
Antimicrobial resistance genotypee (n)
ST24 Ia (9) bca PI-2a tetM(9)
ST452 IV (2) bca PI-1+PI-2a
ST498 Ia (6) bca PI-2a tetM(6)
CC130 (n = 1)
ST130 IX (1) bca PI-2a
aCC, clonal complex; ST, sequence type.
bNT, non-typeable.
cAlp, alpha/alpha-like protein.
dM, resistance to macrolides; MLSB, resistance to macrolides, lincosamides and streptogramins B. The prefix letter refers to the constitutive expression of this phenotype (cMLSB ) or
inducible expression of the phenotype (iMLSB ).
eAll different combinations of antimicrobial resistance genes are presented independently. The erm and mef genes are responsible for the MLSB and M phenotypes respectively while
the tet genes confer resistance to tetracycline.
FIGURE 2 | Erythromycin and clindamycin resistance in the study period.
(Figure 1), we observed significant fluctuations in the number
of disease cases in the first years of the study, with a potential
increase in infections taking place after 2011 (Figure 1). While
this increment did not reach statistical significance (p = 0.08),
our observations support the notion that the implementation
of universal screening and IAP may have had a limited impact,
and is not currently causing further decreases in neonatal
invasive infections in Portugal. In agreement with our findings,
in England and Wales (Lamagni et al., 2013), the Netherlands
(Bekker et al., 2014), and Iceland (Oladottir et al., 2011), neonatal
invasive disease has been shown to increase over time in spite of
the implementation of obstetric risk-based recommendations for
the prevention of GBS disease.
In a previous study in which we compared the GBS
populations associated with vaginal carriage in pregnant women
and invasive neonatal infections in Portugal, serotypes Ia and III
amounted to 69% of all invasive isolates, and were statistically
associated with EOD and LOD, respectively (Martins et al.,
2007). In the same study, an overrepresentation of serotype
III was found in isolates recovered from the CSF, particularly
among LOD cases (Martins et al., 2007), in agreement with other
reports suggesting an association of this serotype with meningitis
(Manning et al., 2009). In this collection, serotypes III and Ia were
even more dominant, together accounting for 81% of all isolates,
similarly to what has been reported recently worldwide (Ferrieri
et al., 2013; Lamagni et al., 2013; Meehan et al., 2014; Teatero
et al., 2014). Even though serotype III was the most frequent
among meningitis cases (n = 20/26; 77%), this association was
not statistically significant.
Only four isolates did not cluster in any of the five most
frequent CCs, together responsible for the majority of invasive
infections in humans: CC1, CC10, CC17, CC19, and CC23
(Bekker et al., 2014; Meehan et al., 2014; Teatero et al., 2014).
We found no significant differences in the relative frequency of
CCs over time, indicating that the genetic lineages responsible
for neonatal infections in Portugal have been dominant over
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a significant time-span. Half of our collection was part of the
CC17 hypervirulent lineage, sharing the same type III capsular
polysaccharide, the surface protein gene rib and the combination
of PI-1 and PI-2b, with the exception of a small subset of theses
isolates carrying only PI-2b, a finding not previously observed
in other CC17 isolates from Portugal (Martins et al., 2013).
A recent study from Canada, using whole genome sequencing
analysis, revealed the loss of PI-1 in a group of CC17 isolates
and integration in the same genomic location of a mobile
genetic element carrying multiple antimicrobial resistance genes
(Teatero et al., 2016). Another recent publication from China
confirmed and extended these findings, further discriminating
the CC17/PI-2b isolates into two groups, distinguishable by their
antimicrobial resistance profiles, namely lincomycin resistance
associated with the presence of lnu(B) gene (Campisi et al.,
2016). In our subset of CC17/PI-2b, all but two isolates
were simultaneously resistant to erythromycin, clindamycin,
tetracycline and streptomycin, and carried the erm(B), tet(O),
aph(3′)-II, and ant(6)-Ia genes (Table 2). We found that
our CC17/PI-2b also presented resistance to kanamycin and
lincomycin, which would place them in the lincomycin resistant
sublineage according to Campisi (Campisi et al., 2016). However,
none of the our isolates harbored the lnu(B) gene, raising the
possibility that our strains represent yet another sublineage of
CC17/PI-2b.
Taken together with the fact that all our CC17/PI-2b isolates
were recovered after 2010, our data suggests that highly
resistant sublineages emerged recently and persist within the
hypervirulent clone. To our knowledge this is the first report
of a CC17/PI-2b lineage in Europe. However, considering that
aminoglycoside susceptibility testing is not routinely performed,
and given the lack of specific guidelines for streptococci, these
highly resistant isolates may be expanding unnoticed in other
countries.
Serotype Ia was represented by two sublineages within
CC23: ST23/eps/PI-2a and its DLV ST24/bca/PI-2a. While ST23
and SLVs were dominant among EOD, ST24 and SLVs were
associated with LOD cases (p < 0.001), indicating that within
the same clonal complex, particular sublineages may be better
adapted to cause specific disease presentations. Furthermore,
the proportion of ST24 and SLVs within CC23 appears to be
increasing when compared to our previous studies. While in
this collection the ratio ST24/CC23 was 34% (n = 17/50),
in a previous study including both invasive, non-invasive and
colonization strains it was 26% (n = 18/69) (Martins et al.,
2013). Taken together, these data suggest that not only is
ST24 well established in the Mediterranean region, but its
frequency may be increasing together with a higher propensity to
cause LOD.
A small number of isolates was represented by ST1/alp3/PI-
1+PI-2a. This genetic lineage is dominant among serotype V
isolates and has been mostly found among invasive disease cases
in non-pregnant adults (Martins et al., 2012; Meehan et al., 2014).
An interesting finding in our study was a subset of serotype
Ib isolates identified as ST1/alp3/PI-1+PI-2a. Considering that
we have not found other serotype Ib isolates with these
characteristics in any of our previous studies, as well as in the
literature, it is likely that these isolates are the result of a recent
capsular switching event (Martins et al., 2010).
Penicillin and ampicillin are first line drugs for prevention
and treatment of GBS disease. Penicillin-allergic patients should
be given clindamycin, and vancomycin is the option for
clindamycin-resistant isolates (Verani et al., 2010). In our
study, macrolide and lincosamide resistance rates increased
significantly over time (p < 0.001) (Figure 2), similarly to what
has been reported elsewhere (Castor et al., 2008; Lamagni et al.,
2013). Even though overall macrolide resistance among neonates
(16.1%) was higher than previously documented among non-
pregnant adults (12.9%) in Portugal (Martins et al., 2012),
these difference hide fluctuations in time. In fact, in the years
common to both studies (2005–2008), macrolide resistance
among neonates ranged between 3.9 and 9.1% (Figure 2) whereas
among adults it ranged between 14.0 and 20.5% (Martins et al.,
2012). These data show that in the same period, macrolide
resistance among non-pregnant adults was much higher than
in neonates and that resistance in the neonatal isolates has
increased significantly only in recent years. Furthermore, in
the present study, the cMLSB phenotype was overrepresented
and associated with the erm(B) gene, in contrast to that
observed previously among non-pregnant adults, in which
macrolide resistance was evenly distributed among the cMLSB
and iMLSB phenotypes, with the erm(A) [erm(TR) subclass]
gene being the most frequent (Martins et al., 2012). In both
studies resistance was mostly found within the same genetic
background, represented by ST1/alp3/PI-1+PI-2a. However, this
lineage expressed serotype V in non-pregnant adults, but in this
study presented both serotypes V and Ib, raising the possibility
that antimicrobial use has been contributing to the selection
and expansion of resistant clones with new serotype/genotype
combinations.
GBS causing invasive disease among neonates in Portugal
are characterized by a limited number of serotypes and genetic
lineages. While the dominance of serotype III and higher
prominence of serotype Ia have been described worldwide,
diversification within these serotypes appears to be ongoing,
as illustrated by the increasing frequency of ST24 among
serotype Ia and the recent emergence of highly resistant
lineages within CC17. Antimicrobial resistance has a significant
impact in clinical practice, not only in preventive strategies
such as IAP but also in the empirical therapy for treatment
of GBS infections. The increasing burden of GBS disease
and dynamic nature of this pathogen substantiate the need
for detailed characterization of the genetic lineages causing
infections as well as for continued monitoring of antimicrobial
resistance.
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